Formulary considerations for treating psychiatric disorders: Schizophrenia

E. Risby, D. Donnigan, Charles Nemeroff

Research output: Contribution to journalArticle

Abstract

Schizophrenia is a severe psychiatric disorder that causes major public health problems. Pharmacotherapy for the condition is divided into two groups: conventional (neuroleptic) and atypical antipsychotics. Conventional agents are effective against positive symptoms of schizophrenia and have a low acquisition cost; however, the risk of significant adverse effects-extrapyramidal symptoms, tardive dyskinesia, and neuroleptic malignant syndrome-limit their use. Atypical antipsychotics, however, appear to provide greater efficacy, including effectiveness against both positive and negative symptoms, than the neuroleptics and, in general, have a more favorable side effect profile. This article reviews both the conventional and atypical treatments available for the treatment of schizophrenia.

Original languageEnglish
Pages (from-to)142-155
Number of pages14
JournalFormulary
Volume32
Issue number2
StatePublished - Jan 1 1997
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this